Search

Highlights from the SWG

EHA2023 CongressThe EHA2023 Congress was held in Frankfurt, Germany, in June 2023. Guideline sessionTitle‘The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children.

Read more

Highlights from the SWG

The SWG organized a EHA scientific workshop entitled: “Shaping the future of MSC Therapy” in Amsterdam from November 23-25, 2017.

Read more

Highlights from the SWG

Standards for functional precision medicine projectStandards for functional precision medicine, a project initiated by EHA's SWG on Precision Hematology, received a 2023 SWG Grant and is currently underway.

Read more

Highlights from the SWG

The following activities, which were organized by EMN, also constitute contributions to and participation in the work of the EHA SWG on Multiple Myeloma.

Read more

Highlights from the SWG

Participation in EHA and ASH congresses. Planning of new common trials. Conduct of annual EMSCO meeting in Nice in October 2023.

Read more

Highlights from the SWG

Joint work with the International Society on Thrombosis and Haemostasis (ISTH), the European Association for Haemophilia and Allied Disorders (EAHAD), and the European Stroke Organisation (ESO) to produce guidance on antithrombotic treatment in patients with hemophilia.

Read more

Highlights of the SWG

SWG business meetingWe held a key strategic SWG business meeting on November 29, 2023, at the EHA offices in The Hague. During the meeting, we discussed the future plans and priorities of our SWG.

Read more

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

Read more